Search
Elranatamab
go.drugbank.com/drugs/DB15395ApprovedInvestigationalIt is a humanized immunoglobulin 2-alanine kappa antibody derived from two monoclonal antibodies (mAbs), an anti-BCMA mAb and an anti-CD3 mAb,[A261060] each of which contributes one heavy chain and one … [L47820] Elranatamab was also approved by the European Commission on December 8, 2023.[L50437]
Olsalazine
go.drugbank.com/drugs/DB01250Approved[A257078] Olsalazine comprises two mesalamine molecules joined by an azo bridge, which is cleaved in the colon. … Olsalazine is an aminosalicylate and a prodrug of [mesalamine] (5-aminosalicylic acid, 5-ASA).
Sufentanil
go.drugbank.com/drugs/DB00708ApprovedInvestigationalSufentanil is an opioid analgesic that is used as an adjunct in anesthesia, in balanced anesthesia, and as a primary anesthetic agent. … Consideration may be made in the future for the use of the sublingual form in the US military in cases where analgesia is required immediately [L4718].
Synonyms: N-(4-(Methoxymethyl)-1-(2-(2-thienyl)ethyl)-4-piperidinyl)-N-phenylpropanamide, N-(4-(Methoxymethyl)-1-(2-(2-thienyl)ethyl)-4-piperidyl)propionanilideLorlatinib
go.drugbank.com/drugs/DB12130ApprovedInvestigationalIt was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-positive non-small cell lung cancer, followed by an expanded approval in 2022 to … include lorlatinib as a first-line treatment option in advanced ALK-positive NSCLC.
Capivasertib
go.drugbank.com/drugs/DB12218ApprovedInvestigationalmetastatic breast cancer with one or more alterations in PIK3CA/AKT1/PTEN gene(s) in combination with [fulvestrant]. … [A262021] The PIK3/AKT pathway is one of the most commonly activated pathways in breast cancer, mainly through the constitutively active mutation in AKT1, loss of function mutation in PTEN, a negative
Omidenepag isopropyl
go.drugbank.com/drugs/DB15071ApprovedThe use of an EP2 receptor agonist such as omidenepag represents an alternative in these scenarios. Omidenepag IOP-lowering effect is comparable to the one observed with [latanoprost]. … [A253253] In 2018, omidenepag isopropyl was approved in Japan for the treatment of glaucoma and ocular hypertension.[A253268] In September 2022, the FDA approved the use of omidenepag isopropyl.
Categories: Receptors, Prostaglandin E, EP2 Subtype, agonistsSynonyms: isopropyl N-(6-(((4-(1H-pyrazol-1-yl)benzyl)(3-pyridinylsulfonyl)amino)methyl)-2-pyridinyl)glycinateAcetylcarnitine
go.drugbank.com/drugs/DB08842ApprovedInvestigationalAcetylcarnitine can be synthesized, but it is also naturally found in adequate amounts in healthy humans. … Acetylcarnitine is an investigational drug in the United states, Italy, United Kingdom, China, Israel, and Norway, and it is approved in Italy, Portugal, Argentina, Chile, Philippines, Australia, and India
Influenza B virus B/Phuket/3073/2013 hemagglutinin antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB14407ApprovedInvestigationalInactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.
Mixtures: Efluelda Tetra Injektionssuspension in einer FertigspritzeLevoketoconazole
go.drugbank.com/drugs/DB05667Approvedchanges in body composition, neuropsychiatric effects, changes in blood pressure and chemistry, and opportunistic infections. … [A244083] Levoketoconazole is one of two enantiomers present in racemic [ketoconazole].
Dihydroergotamine
go.drugbank.com/drugs/DB00320ApprovedInvestigational[A239569] The recently approved Precision Olfactory Delivery technology developed by Impel Neuropharma technology has correlated with an increase of 3-fold in Cmax and 4-fold in AUC despite the solution … Dihydroergotamine is used as an abortive therapy for migraines.
Synonyms: (2R,4R,7R)-N-[(1S,2S,4R,7S)-7-benzyl-2-hydroxy-4-methyl-5,8-dioxo-3-oxa-6,9-diazatricyclo[7.3.0.02,6]dodecan-4-yl]-6-methyl-6,11-diazatetracyclo[7.6.1.02,7.012,16]hexadeca-1(16),9,12,14-tetraene-4-carboxamide